New ABPI president goes all-out patient-centric
The ABPI, it seems, has taken on the role of patient advocate, if listening to the trade body’s new president is anything to go by.
Read MoreAuthor: Katrina Megget
UPDATED: AstraZeneca rejects Pfizer’s improved final bid
Pfizer’s sweetened bid to acquire AstraZeneca for £55, up from £50 per share, has been rejected.
Read MoreTamiflu fails to support its scientific claims, review finds
NHS England has confirmed it is in the dark over how much money it has received from the rebates pharma has paid as part of the new Pharmaceutical Price Regulation Scheme
Read MoreCaffeine could be cure for Alzheimer’s, tests in mice suggest
Coffee could be the go-to drug to beat Alzheimer’s disease after research found caffeine has a positive effect on tau deposits in the neurodegenerative disease.
Read More£4 million MedCity launched in London
London Mayor Boris Johnson has laid out his plans to make the UK’s capital a med-tech rival to its financial services sector and take on the science hubs of Boston and Singapore.
Read More- MHRA to open new Northern Ireland hub to strengthen UK‑wide life sciences collaboration
- Novo Nordisk data shows oral semaglutide delivers significant weight loss in phase 3 trial
- Enterprise reports positive phase 2 data for inhaled ENaC blocker in cystic fibrosis
- SMC backs first-line metastatic bladder cancer combination after trial results
- Poolbeg secures Canadian patent for POLB 001 in cancer immunotherapy‑induced CRS
